Zacks.com on MSN1h
ABBV's Acquisition Spree Continues: Buy, Sell or Hold the Stock?AbbVie ABBV continued its acquisition spree with the announcement of a definitive agreement to acquire private biotech Nimble ...
The Nimble acquisition, which follows the $1.4 billion buy of Aliada Therapeutics in October, will help AbbVie rebuild and ...
Even as Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla slowly roll out onto the market, experts question the efficacy of ...
AbbVie has announced that it has completed its acquisition of Aliada Therapeutics. With the completion of the acquisition, ...
Buying Nimble Therapeutics represents AbbVie's latest deal to build out a pipeline in the wake of fading sales of its once ...
Shares of AbbVie Inc. oscillated between gains and losses Friday as the company’s latest acquisition drew mixed reactions ...
AbbVie is paying $200 million to snap up Nimble Therapeutics, a Roche spinout working to develop oral peptide treatments in the autoimmune space. | AbbVie is paying $200 million to snap up Nimble ...
AbbVie (ABBV) and Nimble Therapeutics announced a definitive agreement under which AbbVie will acquire Nimble, including its lead asset, an investigational oral peptide IL23R inhibitor in preclinical ...
In the wake of Keros Therapeutics Inc.’s voluntary halt of dosing in two arms of its phase II study of pulmonary arterial hypertension, the company’s stock (NASDAQ:KROS) has crumpled after a year’s ...
We recently published a list of 10 Best Safe Stocks To Buy According to Analysts. In this article, we are going to take a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback